{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:23:27Z","timestamp":1788985407683,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>We present the case of a 22-year-old male who was first diagnosed with chronic recurrent multifocal osteomyelitis (CRMO) at the age of 16 years. During treatment with the tumor necrosis factor (TNF)-alpha inhibitor adalimumab, he developed severe palmoplantar psoriasis that affected his quality of life and necessitated discontinuation of the drug despite its efficacy against CRMO. Subsequent treatment with the interleukin (IL)-17a inhibitor secukinumab did not improve the psoriasis and led to a recurrence of the osteomyelitis. Therefore, the TYK-2 inhibitor deucravacitinib, approved in 2023 for the treatment of moderate to severe plaque psoriasis, was initiated. This resulted in clinical and morphological complete and sustained remission of CRMO within 12 weeks and a significant improvement of the psoriasis after six months of treatment with no occurrence of severe adverse events. To our knowledge, this is the first case report demonstrating complete and safe remission of CRMO associated with palmoplantar psoriasis treated with the TYK2 inhibitor deucravacitinib.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1480810","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:52:25Z","timestamp":1747900345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis"],"prefix":"10.3389","volume":"16","author":[{"given":"Caroline","family":"Glatzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick-Pascal","family":"Strunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Holl-Wieden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"959575","DOI":"10.3389\/fimmu.2022.959575","article-title":"Chronic recurrent multifocal osteomyelitis. A narrative and pictorial review","volume":"13","author":"Sergi","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/s11914-017-0405-9","article-title":"Chronic recurrent multifocal osteomyelitis (CRMO): presentation, pathogenesis, and treatment","volume":"15","author":"Hofmann","year":"2017","journal-title":"Curr Osteoporos Rep"},{"key":"B3","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/children8090792","article-title":"Role of diagnostic imaging in chronic recurrent multifocal osteomyelitis (CRMO) in children: an observational study","volume":"8","author":"Kope\u0107","year":"2021","journal-title":"Children"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1097\/MOP.0000000000000970","article-title":"Chronic recurrent multifocal osteomyelitis: diagnosis and treatment","volume":"33","author":"Moreno-Mateo","year":"2021","journal-title":"Curr Opin Pediatr"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-016-3466-7","article-title":"Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO)","volume":"36","author":"Hofmann","year":"2016","journal-title":"Rheumatol Int"},{"key":"B6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clim.2012.07.012","article-title":"Attenuated TLR4\/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression","volume":"145","author":"Hofmann","year":"2012","journal-title":"Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.2005.030759","article-title":"Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia (Majeed syndrome)","volume":"42","author":"Ferguson","year":"2005","journal-title":"J Med Genet"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1002\/art.39013","article-title":"A large national cohort of French patients with chronic recurrent multifocal osteitis","volume":"67","author":"Wipff","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B9","article-title":"The neglected and untreated pains of CRMO and SAPHO syndrome","author":"Sinnappurajar","year":"2022","journal-title":"Oxford Univ Press"},{"key":"B10","article-title":"The jigsaw puzzle of chronic non-bacterial osteomyelitis: are anti-IL17 therapies the next piece","author":"Goenka","year":"2020","journal-title":"Oxford Univ Press"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac461","article-title":"Chronic recurrent multifocal osteomyelitis and tofacitinib: a case series","volume":"62","author":"Lanis","year":"2023","journal-title":"Rheumatology"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1197273","DOI":"10.3389\/fmed.2023.1197273","article-title":"Pyoderma gangrenosum following anti-TNF therapy in chronic recurrent multifocal osteomyelitis: drug reaction or cutaneous manifestation of the disease? A critical review on the topic with an emblematic case report","volume":"10","author":"Romagnuolo","year":"2023","journal-title":"Front Med"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keh295","article-title":"Pamidronate in the treatment of childhood SAPHO syndrome","volume":"43","author":"Kerrison","year":"2004","journal-title":"Rheumatology"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.2174\/138920210793175921","article-title":"Clinical, molecular, and genetic characteristics of PAPA syndrome: a review","volume":"11","author":"Smith E","year":"2010","journal-title":"Curr Genomics"},{"key":"B15","first-page":"100211","article-title":"Paradoxical psoriasis: The flip side of idiopathic psoriasis or an autocephalous reversible drug reaction","volume":"7","author":"Lu","year":"2023","journal-title":"J Trans Autoimmun"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1007\/s40272-023-00581-y","article-title":"Golimumab in children with chronic recurrent multifocal osteomyelitis: a case series and review of the literature","volume":"25","author":"Yang","year":"2023","journal-title":"Pediatr Drugs"},{"key":"B17","article-title":"Case series of psoriasis associated with tumor necrosis factor-\u03b1 inhibitors in children with chronic recurrent multifocal osteomyelitis","volume":"4","author":"Campbell","year":"2018","journal-title":"JAAD Case Rep"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1111\/ddg.14585_g","article-title":"TYK2-Inhibition: Potenzial bei der Behandlung chronisch-entz\u00fcndlicher Immunerkrankungen","volume":"19","author":"Ghoreschi","year":"2021","journal-title":"JDDG: J der Deutschen Dermatol Ges"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1222129","DOI":"10.3389\/fimmu.2023.1222129","article-title":"The effect of cytokines on osteoblasts and osteoclasts in bone remodeling in osteoporosis: a review","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","year":"2019","journal-title":"Nat Rev Drug Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1480810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:52:28Z","timestamp":1747900348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1480810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1480810"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1480810","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"article-number":"1480810"}}